Novartis Q4 Results

↓ ↑ Content Click below to navigate through the document Company overview Financial review Conclusions Appendix FabhaltaⓇ1: FDA approved with compelling label in PNH Positive early launch signals, expect modest ramp Strong product profile reflected in label Compelling data . References • . Hb improvement vs. C5i in patients with residual anemia Transfusion avoidance Comprehensive IVH and EVH control Broad population Oral administration First oral monotherapy REMS requirements similar to other complement inhibitors · Adults with PNH . Naive and switch 300781189209 GROWTH FABHALTA (iptacopan) 200 mg capsules Reco NDC 0078-1189-20 Rx only Eest FABHALTA (iptacopan) capsules Ston екси and 200 mg Dispenso with accompanying Medication Guide. 60 capsules Swallow the capsules whole. Do not open, break, or chew capsules NOVARTIS mac DE E . Demonstrated safety profile Positive early launch signals, expect modest ramp Launch execution • Promotion started early Dec incl. at ASH . REMS and patient support programs live First patients initiated shortly after approval Sentiment · Positive HCP sentiment on efficacy, safety and oral profile Strong interest from patients/patient groups Access • Distribution with two national specialty pharmacies Bridge support in place pending payer coverage PNH - paroxysmal nocturnal hemoglobinuria. C5i complement 5 inhibitor. IVH - intravascular hemolysis. EVH - extravascular hemolysis. REMS-risk evaluation and mitigation strategies. HCP - healthcare professional. 1. Iptacopan is the generic name for unapproved indications. □ NOVARTIS | Reimagining Medicine. ASH American Society of Hematology. Novartis Q4 Results | January 31, 2024 15

View entire presentation